2020 Virtual Annual General Meeting of BioNTech SE

on Friday, 26. June 2020, at 10.00 a.m.

Report of the Management Board – Prof. Ugur Sahin (CEO)

Ladies and Gentlemen, dear shareholders and holders of ADS, dear employees,

I would have liked to have been standing before you personally today to review the 2019 financial year together. To mark the occasion, we are required to hold our first Annual General Meeting as a listed company virtually. However, this should not diminish the enthusiasm for the important progress we made last year.

Let us start with the big picture: where will the journey for BioNTech take us? We - the Management Board, the Supervisory Board, our employees and partners - have a clear goal: BioNTech should become one of the world's leading biotechnology companies.

We laid the foundation for our successful 2019 financial year 12 years ago. We founded "Biopharmaceutical New Technologies" - which is what BioNTech actually stands for - with the clear goal of revolutionizing cancer medicine. We want to provide every patient with an individualized therapy.

The focus on the people who desperately need our treatments and vaccines is the linchpin of our strategy. To this end, we develop and use future technologies that enable us to use the full potential of the patient's own immune system for the treatment and prevention of diseases.

Our technologies and competencies allow us to develop solutions far beyond the field of cancer medicine, e.g. for the prevention and treatment of infectious diseases and many other serious illnesses.

The COVID-19 outbreak shows just how important this is.

2019 was a year of transformation for us - an important chapter in our history combined with the goal of becoming one of the leading biotech companies:

- First: We have consistently pursued our strategy and launched six clinical trials last year.

  At the end of 2019, the total list of cancer therapeutics developed by BioNTech had thus increased to 10 product candidates to be tested in humans.

- Secondly, we have consistently expanded our production capacities in Germany. Manufacturing remains an important strategic priority for us. The current pandemic shows how important local production capacities are.

- Thirdly, to enable our research through solid financing, we have successfully attracted investors: Firstly, through the Series B financing round, secondly through the IPO in the USA.

In 2019, we raised $676.5 million in capital and, with the IPO, have put the company in a good position for the future. My colleague Sierk Poetting will go into this in more detail in a moment. There were also encouraging developments at the operational level in 2019. We are working with more than 1,300 colleagues on the various building blocks of our strategy.

In order to develop new drugs and market them worldwide, we are continuously expanding our co-operations, our team and our own production facilities.

Our technologies and expertise allow us to develop solutions for the prevention and treatment quickly and flexibly. Not only for cancer, but also for infectious diseases such as COVID-19.

Despite the current focus on our COVID-19 project, we will continue to use 2020 to continue our core business and the initiatives launched in 2019.

Our main focus is always on generating added value: for our patients, for our employees and for you: our shareholders and holders of ADSs.

On behalf of the entire Management Board, I would like to take this opportunity to thank our colleagues on both sides of the Atlantic for their immense contribution. It is your dedication, your innovation and your passion that contributes every day to our mission to change medicine for the better.

It fills me with pride to see what our team is doing in the current situation and how each individual is committed. How our colleagues organize the daily routine around the job, how they work in an agile and focused manner, how they deliver results of the highest quality in a short time. Many colleagues have outgrown themselves in the past weeks. We would like to thank you.

Let us look back on the past financial year.

There are a few milestones that I would like to highlight for you:

Right at the beginning of the year, we were able to further expand our research collaboration with Sanofi for the development of mRNA-based, intratumorally applied therapeutics for solid tumors. In the course of this, Sanofi has invested 80 million Euros in BioNTech. This shows the great confidence we have built in this partnership. In addition, our first mRNA-based product candidate for intratumoral immunotherapy, BNT131, moved from co-development into the clinical phase. For BNT131 we expect a data update in the second half of this year.

In 2019, we also decided to change our legal form to a European SE. On the one hand, this represents our international orientation. On the other hand, it also broadens the range of our strategic options for future partnerships and for raising capital.

We want to provide every patient with the right therapeutic approach. That is why we do not focus on a single technology. We continue to develop our drug pipeline in order to select the right approach and combination from a diversified spectrum. We are

technology-agnostic. This means that we do not trust a single technology, but rather we ask the question: “Which technology is best suited for a solution approach?”

We develop active ingredients based on mRNA, antibodies, programmable cell therapies and small molecule drugs.

Each technology has its specific strengths, which we intend to further develop and exploit in the future.

We made important acquisitions in antibody development in January and May 2019. These strengthen our portfolio in the long term.

- First of all, MAB Discovery: the exclusive access to the mature proprietary know-how of MAB Discovery significantly expands our range of targeted ligands.

  This enables us to generate new monoclonal antibody candidates directly, quickly and efficiently. We will use the know-how gained together with our existing platforms, including RiboMABS®. RiboMABS is a new class of mRNA-encoded antibodies.

- This allows us to use the patient’s body to make antibodies for the treatment of e.g. gastric cancer and ovarian cancer in an elegant and cost-effective way.

- The second transaction had a similar goal: With MabVax Therapeutics, we acquired an antibody with a novel mode of action in an important indication for the treatment of pancreatic cancer that fits very well into our product pipeline.

We were also able to announce further news regarding our antibody portfolio in our collaboration with Genmab in June 2019. We were able to bring our first jointly developed product candidate, a bi-specific polypeptide-based antibody called BNT311, into clinical testing. Only four years after the start of this project. I see this as a sign of our highly productive partnership. BNT312, the second product candidate of this collaboration, has also successfully advanced into clinical testing. Both bi-specific antibodies are a further development of the checkpoint inhibitor concept. They cleverly combine the inhibitory PD-1:PD-L1 signaling axis with the conditional stimulation of T cells.

2019 was an important and very successful year for BioNTech from a capital markets point of view. In July, we were able to close one of the largest European Series B financings.

Perhaps the biggest highlight was the leap onto the international stock exchange of Nasdaq in New York. October 10, 2019 will therefore remain in our memory for a long time to come.

We are thus one of eight German companies listed on the US technology stock exchange. In keeping with the times, we rang in the festivities using a tablet computer instead of a bell.

In addition, our whole team was able to be part of this unique event by going live. This was very important for us, because it was our team’s great personal commitment over many years that made the IPO possible.

Towards the end of 2019, the European Investment Bank also assured us of its support. As part of the Investment Offensive for Europe, we received a 50 million Euro loan. We will use this loan to increase our research, development and production capacities for our mRNA-based cancer therapies and to create additional jobs.

2019 was also a year of transformation for BioNTech in that we expanded our mRNA platform in the field of infectious diseases. With the Bill and Melinda Gates Foundation we have gained an important partner with a large network.

Under the terms of the partnership, we have received an initial upfront payment of $55 million to support us in the development of HIV and tuberculosis vaccine and immunotherapy candidates. This strategic step - to expand our portfolio in infectious diseases in addition to cancer - now also benefits our COVID 19 program. We can say that our timing was perfect!

But also the big picture and especially our pipeline have developed wonderfully: We have initiated a total of six clinical trials. These studies use four therapeutic platforms and cover two classes of compounds. By the end of 2019, we had ten product candidates in eleven clinical trials.

We have also successfully laid the foundation for the start of several registration trials in 2020. This not only demonstrates the great potential of our platforms. It also underscores the breadth of our unique pipeline and our ability to rapidly implement our vision.

We have also taken the tailwind from last year into 2020 and have made a good start.

Right at the beginning of the year, we published pre-clinical data for our first CARVac program BNT211 in the journal Science. Our focus on top-class research evaluated by the scientific community is deeply rooted in our corporate philosophy. BioNTech stands for sound science. This is why we will continue to share our research results with the public in the coming years.

BNT211 is an approach that enables CAR-T cell therapies in solid tumors. With this product candidate, we have for the first time presented our capabilities in cell therapy development to the public. We have even gone one step further. The combination with an mRNA booster is unique and could enable CAR-T cell therapies to be successfully used for the treatment of solid tumors.

The start of clinical development is still planned for 2020.

A strategic highlight this year is the expansion of our US presence. The acquisition of Neon Therapeutics in the U.S. biotech hotspot Cambridge near Boston will provide us with a new center for research and development. The experienced colleagues complement our existing team wonderfully. We are thus further expanding our expertise in the field of T-cell therapies, particularly with regard to clinical development.

When the outbreak of a new virus in China became public in early 2020, we did not hesitate.

As some of you know, I read two major articles in the medical journal Lancet. They were about pneumonia caused by a new type of virus, which was obviously transmitted from person to person.

I was alarmed by the rapid spread of COVID-19 infections and the severity of the disease in certain patient populations. As recently as January, we worked with colleagues to develop a strategy on how we can help to keep an impending pandemic under control.

The Management Board and the Supervisory Board quickly agreed: We felt obliged to use our technology and immunotherapy expertise to develop a well-tolerated and potent vaccine as quickly as possible.

We are convinced that we can make a tangible difference with our approach. In mid-January, we launched the global development project Lightspeed. We assembled new teams and formed a global alliance with two renowned partners - Pfizer and Fosun Pharma.

We have successfully initiated studies in the USA and Europe. In parallel, we are expanding our production capacities in Germany.

To date, we are the only company that is clinically testing several vaccine candidates in parallel, and we are doing this on several continents. This also demonstrates the strength of our global corporate strategy.

We are already investing heavily in expanding our production capacities in order to be able to provide vaccine doses for commercial distribution immediately in the event of a possible approval of our vaccine candidate BNT162. Production lines at our two sites in Idar-Oberstein and Mainz are already running around the clock in some cases. The loan of up to 100 million euros from the European Investment Bank concluded in June is a further important component in this regard.

Together with our partner Pfizer, our goal is to enable the production of millions of vaccine doses by 2020. By 2021, we would like to expand capacity to hundreds of millions of doses per year.

We also plan to publish the first clinical results of our Phase 1/2 study shortly. In less than three months, we have managed to carefully evaluate our candidates in the pre-clinical phase and have received approval from international authorities to start clinical trials.

A pandemic like the one we are currently experiencing requires a rapid response without compromising safety and efficacy. We are convinced that mRNA vaccines will be able to do this balancing act.

As with many other companies, the pandemic also has an impact on our business processes. We are continuously monitoring possible consequences for our study programs.

Our goal remains to initiate Phase 2 trials of our iNeST programs BNT111, BNT113 and BNT122 as adjuvant therapy in partnership with Roche and Genentech, respectively.

However, the pandemic has partially impaired recruitment at the study centres. For example, the restrictions and travel restrictions for patients. The ongoing studies on BNT111 and BNT114 are less affected by this. For the trials planned for 2020 and 2021, we are working on a plan to start the Phase 1 trials immediately, if circumstances permit. We will keep you regularly updated on this in our quarterly reports and inform you about further steps.

In summary, in the past 18 months we have set many important milestones to put BioNTech on a successful path and to further consolidate and expand our global presence. This includes not only the progress made in our cancer and vaccine programs, but also the operational progress in expanding our research and production capacities. This will enable us to provide a global supply of our product candidates - a significant advance in the COVID 19 program, but also relevant for our cancer therapy studies.

But more important than looking back at what has been achieved is looking forward:

Over the next 18 months, we expect to reach some important milestones that will bring us closer to our vision of individualized cancer therapy.

These include data updates in several FixVac and iNeST programs and in our collaboration with Genmab on BNT311. In addition, the first results from our COVID-19 program will be reported. With the COVID-19 vaccine, the first product candidate developed by BioNTech could, if approved, find worldwide application.

I am looking forward to 2020 and 2021 with great enthusiasm, and I am certain that every crisis, every enormous challenge is an opportunity for innovation to prove itself. We are working flat out on the further development of our product candidates and we want to make our contribution to overcoming this crisis.

But we want to keep in mind - drug development is a long process. Not only we, but also you, dear shareholders and ADS holders, need more staying power here than at companies in other industries. The good news is that we have achieved a lot and have a lot more to do. We need your support and would be extremely grateful if you would continue to accompany us supportively.

I would like to thank all of you who are attending our first Annual General Meeting since the IPO today for the trust you placed in us last year. I will now hand over to my colleague Sierk Poetting.